Skip to content
Main Navigation
About us
Meet the team
Partnerships
Research
Molecular Microbiology
Immunity and Inflammation
Population Health and Biology
Clinical and Public Health Research
Publications
Opportunities
Job opportunities
Seed grants
PhD/Honours
News & Events
Contact
Home
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
Lancet Infect. Dis., Vol 22(11), pp1565-1576